Search

ResumoObjetivoIdentificar e quantificar os efeitos adversos associados à vacina papillomavirus humano 6, 11, 16 e 18 (recombinante) em adolescentes.Fontes de dadosRevisão sistemática de ensaios clínicos randomizados nas bases de dados do PubMed, SciELO e Lilacs. Foram incluídos artigos que abordavam a segurança da vacina em menores de 18 anos e que comparavam a vacina papillomavirus humano 6, 11, 16 e 18 (recombinante) com grupo controle. Foram feitas metanálises para os desfechos de dor, eritema, edema e febre com o uso de ensaios clínicos com escore de Jadad máximo.Síntese dos dadosForam incluídos 14 estudos. Os efeitos adversos mais comuns relacionados à vacina foram intercorrências sem gravidade (dor, eritema, edema e febre). Cinco estudos foram usados para as metanálises, incluindo os desfechos: Dor – Diferença de Risco (DR)=11% (p

Objectives Comparison between two electronic methods of antepartum fetal assessment in hypertensive pregnant women. Methods Comparison of conventional cardiotocography tracing and transabdominal fetal electrocardiography with the use of the fetal monitor AN24 (Monica Healthcare), in women with gestational age ⩾34 weeks, single fetus, with hypertensive disorders according to the criteria of NHBPEP-2000 at Guilherme Alvaro Hospital – Santos/SP – Brazil (Dec/2013–Jun/2014). The cardiotocography recorded the fetal heart rate by a Doppler transducer, dependent on correct identification of fetal positioning, the AN24 detected electrophysiological signals using electrodes arranged on the maternal abdomen. The tests were performed according to standard recommendation; variables evaluated: gestational age, number of pregnancies, parity, baseline, variability, body mass index (BMI), obesity, preservation of mobility adhesion, successful recording, Preparation time ( 20″), facility of captation/stability of signal in the group with BMI > 30, agreement in diagnostic classification (ACOG Practice Bulletin 106, 2009). Results Of the 10 tracings evaluated: 03 pregnant women with pre-eclampsia, 07 with chronic hypertensive (06 developed superimposed pre-eclampsia). The AN24 monitor preserved the mobility and made it easier to obtain the registration in women with BMI > 30 with better adherence in this group once it dismissed the additional manipulation of the abdomen to obtain registration. Gestational age average (weeks) 34.8 Good capitation MONICA 80% Number of pregnancies (average) 4.4 Good capitation cardiotocography 50% Parity (average) 2.5 Preparation time MONICA ( 70% Base line fetal heart rate (average) 134.6 Time procedure MONICA (>20′) 80% Variability (oscillation 6–25 bpm) 67% Preparation time cardiotocography ( 90% BMI (average) 37.4 Time procedure cardiotocography (>20′) 90% Obesity 60% Concordance in the classification 100% In the group with BMI ⩾ 30 (07 pregnancies), facility of captation/stability of signal was 85%, instead of when BMI ⩽ 30 was 42%. Conclusions We have not identified any differences regarding the quality of analysis fetal vitality between the methods. The easy achievement/continuity of record by AN24 monitor in maternal obesity may indicate that this resource is particularly valuable for this group. Additional studies may increase the information for this research. Disclosures C. Geraldes: None. M. Saco: None. P. Coelho: None. G. Calestini: None. C. Cury: None. F. Fuentes: None. B. Zeiger: None. J. Garcia: None. S. de Toledo: None. R. Guidoni: None. M. Saito: None. F. Sousa: None. C. Mariani Neto: None.

Objectives Evaluate the role of placenta growth factor (PlGF) as a predictor of preeclampsia (PE). Methods Systematic review on Pubmed (february/2014) with descriptor: “(placenta growth factor OR plgf) AND pre-eclampsia/diagnosis”’. A total of 126 articles were found. Items with more than three years of publication, systematic reviews, not related to the topic after reading the abstract and unavailability of the article were excluded. Among the papers which were read in full, three were excluded because they did not use as a predictive factor PlGF, totaling 19 items for the final sample. Results Due to the heterogeneity of the articles found, four groups were defined sorted into 4 groups: Group 1 PlGF isolated Fifteen studies were conducted as a single measure of PlGF and found a decrease in patients with PE; Ten in the first half of pregnancy; five found with lower values when PE early; four found with severe lower PE values Group 2 Relation sFlt-1/PlGF Six studies determined the relationship sFlt-1/PlGF and had an increase in pregnant women with PE values in the second quarter Group 3 Combination of PlGF Doppler velocimetry of uterine arteries Of the eight articles that combined biochemical to biophysical methods, five showed improvement in sensitivity and specificity with the combination, four in the first quarter Group 4 Combination of several biomarkers Three studies investigated various biomarkers, two achieved combination of markers. While Myatt et al. (2012) found increased diagnostic capacity with the association, Myers et al. (2013) did not obtain the same result combining several biomarkers Conclusions It is suggested that PlGF is reduced in PE, alternating the values in the first half of pregnancy, especially early/severe PE. The sFlt-1/PlGF ratio is better in the second trimester of gestation (late when compared to isolated PlGF). Diagnostic ability of PlGF can be extended by associating other methods, especially biophysical. Standardized studies are needed, homogenizing the collection time, cut off values and a way of presentation of the results for the comparison be clear. Disclosures G. Calestini: None. B. Reis: None. D. Labre: None. F. Fuentes: None. F. Sousa: None. L. Wenzel: None. P. Coelho: None. W. Chanwangyen: None. S. Prieto: None. D. Prieto: None. U. Markert: None. N. Sass: None.